Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2016.03.091 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Antiplatelet drugs, such as clopidogrel, ticagrelor, prasugrel, and acetylsalicylic acid, may be associated with a risk of adverse events (AEs). Vanessa's Law was enacted to strengthen regulations to protect Canadians from drug-related side effects (with mandatory reporting of serious adverse events [SAEs]).
Objective: To determine whether Vanessa's Law has led to an increase in SAE reporting among antiplatelet users.
The effect of gene polymorphism on ticagrelor metabolism: an study of 22 CYP3A4 variants in Chinese Han population.
PeerJ
September 2024
School of Pharmacy, Wenzhou Medical University, Wenzhou, China.
Article Synopsis
- Ticagrelor, an oral antiplatelet drug, selectively inhibits the P2Y12 receptor, but can cause side effects such as bleeding and dyspnea, which are linked to its plasma concentration.
- The study aimed to investigate how 22 different CYP3A4 gene variants, found in the Chinese Han population, affect the metabolism of ticagrelor.
- Results showed that most CYP3A4 variants had significant differences in how they cleared ticagrelor, with some having much higher or lower activity than the wild-type, indicating the need for personalized treatment approaches.
Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model.
Health Technol Assess
September 2024
Bristol TAG, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Article Synopsis
- Stroke patients on clopidogrel may face risks from genetic variants that impair how their bodies process the medication; genetic testing can help identify these issues for better treatment targeting.* -
- The study examined whether genetic testing for clopidogrel resistance can lead to a lower risk of future vascular events, especially when using alternative medications like ticagrelor instead of clopidogrel.* -
- Results showed that while two studies indicated a reduced risk of events in genetically tested patients, the evidence was not very strong, and ticagrelor was found to be more effective than clopidogrel in those with genetic variants.*
An interesting case series of ticagrelor induced long QTc.
Int J Cardiol Cardiovasc Risk Prev
September 2024
Department of Cardiology, School of Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
This case series explores three patients who underwent percutaneous coronary intervention (PCI) and experienced prolonged QT intervals under treatment with Ticagrelor. The first case was a female who presented with chest pain and received a Xience stent. The second case involved a male patient who received two Xience stents.
View Article and Find Full Text PDFAdenosine in Interventional Cardiology: Physiopathologic and Pharmacologic Effects in Coronary Artery Disease.
Int J Mol Sci
May 2024
Atherothrombotic Center, Department of Experimental and Clinical Medicine, University of Florence, AOU Careggi, 50134 Florence, Italy.
This review article focuses on the role of adenosine in coronary artery disease (CAD) diagnosis and treatment. Adenosine, an endogenous purine nucleoside, plays crucial roles in cardiovascular physiology and pathology. Its release and effects, mediated by specific receptors, influence vasomotor function, blood pressure regulation, heart rate, and platelet activity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!